BioMarin Pharmaceutical Inc. (BMRN) announced the FDA has accepted for Priority Review the company's PALYNZIQ supplemental Biologics License Application to expand treatment to include adolescents aged 12-17 with phenylketonuria. The FDA has set a PDUFA target action date of Feb. 28, 2026. The sBLA is based on data from PEGASUS, a Phase 3 multi-center open-label randomized controlled study.
The company said it is also working to share the data with the European Medicines Agency with the goal of expanding treatment with PALYNZIQ to include adolescents as young as age 12 in the European Union.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.